Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
Loading...All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
CD200R1 is a type I transmembrane glycoprotein in the immunoglobulin superfamily (IgSF). Binding of CD200 to CD200R1 promotes phosphorylation of the receptor cytoplasmic tail and recruitment of adaptor proteins such as Dok2 and RasGAP, thereby transmitting inhibitory signals that suppress downstream Ras/MAPK-associated activation pathways. The CD200-CD200R1 axis is an important pathway controlling microglial activation and regulating neuroinflammation within the central nervous system, with implications for neuronal protection in neurodegenerative conditions. In peripheral tissues, this receptor-ligand pair acts as an inhibitory mechanism that restrains macrophage activation and helps promote resolution of antimicrobial and wound-healing responses while limiting excessive tissue damage and fibrosis. Dysregulated CD200R1 signaling has also been implicated in inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. In addition, various solid and hematologic tumors may upregulate CD200 and exploit this inhibitory axis to reduce antitumor immune surveillance by myeloid cells. Together, these biological observations support CD200R1 as a potential target for immune modulation, neuroinflammation research, and targeted drug development in oncology.
Fig.1 CD200:CD200R1 axis.1
CD200R1 has a functional scope across several interrelated biological domains:
Accelerate your research of immune checkpoint and neuroinflammation research with our in-house produced recombinant CD200R1 membrane protein catalogue. The unique production challenges of CD200R1 arise from the presence of both Ig-like extracellular domains and single-pass transmembrane topology with glycosylation-dependent folding. To tackle these, we utilize appropriate expression strategies tailored for full-length or ECD formats to produce correctly folded, fully glycosylated CD200R1 constructs that retain native capacity for CD200-binding and immunoreactivity. We provide full-length membrane-bound protein, soluble extracellular domain (ECD) fragments as well as cytoplasmic tail variants. All preparations are exhaustively biophysically validated, ensuring suitability for extensive structural, ligand binding and antibody screening regimes.
Not finding the membrane protein product you need? Contact us to start your one-stop custom service!
You need reliable, reproducible cellular models to understand the biology driven by CD200R1 and to assess potential therapeutics. Stable cell lines are provided that are engineered to express wild-type or disease-associated mouse, and rat CD200R1, as well as lines that modulate the endogenous expression of CD200R1 resulting in loss-of-function studies. These systems are developed for high-throughput ligand screening, NF-κB reporter assays, and myeloid activation profiling, and can be used in multi-phase research projects where consistent experimental outcomes with CD200-expressing target cells co-cultured with monocytes is required.
Not finding the stable cell line product you need? Contact us to start your one-stop custom service!
Our products are high-affinity recombinant antibodies targeting CD200R1 that have been developed for various research applications. These antibodies are generated from advanced recombinant technologies, exhibiting much higher specificity, sensitivity, and batch-to-batch consistency than polyclonal antibodies. We offer CD200R1 recombinant antibodies that are validated in WB, ELISA, FCM, IF, ICC, IHC and IP providing the flexibility for accurate detection or quantification of CD200R1 from various samples including myeloid cell lysates, microglial preparations as well as tissue sections or reconstituted receptor-ligand complexes.
Not finding the recombinant antibody product you need? Contact us to start your one-stop custom service!
We provide specialized custom services for discovering and developing membrane protein and antibody? With the benefit of our broad knowledge in immune checkpoint biology and myeloid cell pharmacology, we are here to support you with:
No, all CD200R1 products/services are for research use only and not intended for clinical diagnosis, prevention, treatment or cure of any disease.
Yes. With flexible pricing tiers, we meet your academic and industrial scale-up needs. Submit your expected volume and timeline via our request-for-quotation portal, and a custom quote will be provided.
Absolutely. The cell engineering group regularly generates tetracycline-inducible systems and CD200R1 co-expressing lines as well as uses NF-κB/STAT3 reporter constructs on how total signal pathway analysis applies.
Yes. Specific clones recognize glycan dependence-only epitopes that appear after Golgi maturation, generating a unique change in electrophoretic mobility by western blot. This enables the monitoring of surface delivery and trafficking fidelity directly, without the need for metabolic labeling or subcellular fractionation.
